Cyprus/Greece/MaltaCyprusGreeceMalta

Tumor marker studies questioned

16.03.2007

Ioannina – Tumor markers are specific to a certain type of cancer and its developmental stage. They are used to estimate a prognosis for the development and treatment of the cancer.
Researchers led by John Ioannidis from the University of Ioannina School of Medicine undertook an empirical approach to reports from studies of these cancer prognostic factors to revise their informational value (J. natl. cancer inst. 99,(3): 236-43). From 20 meta-analyses of cancer prognostic markers, 331 studies were identified. Applying eight quality measures to the study design and assay methods (i.e. blinding and power calculation), they found that estimates of prognostic effects of tumor markers varied considerably and came to the conclusion that the literature was largely unreliable. According to their assessment, improved design and reporting was deemed necessary, given the clinical importance of prognostic markers.

Cyprus/Greece/MaltaCyprusGreeceMalta

26.11.2005

Nicosia - A rare medical condition has been found to be nine times more prevalent in Cypriots living in Paphos than in the rest of Cyprus or the European Union. Results of research carried out by the Neurology and Genetic...

Cyprus/Greece/MaltaCyprusGreeceMalta

26.11.2005

Brussels - The European Union's Agricultural Council has failed to reach a qualified majority for rejecting or upholding the Greek ban on genetically modified (GM) maize Mon 810. EuropaBio, the organization representing Europe's...

Cyprus/Greece/MaltaCyprusGreeceMalta

28.09.2005

Nicosia - US-based Genaissance Pharmaceuticals Inc. announced in September that it will provide its high-throughput genotyping services to Cyprus' Biotronics Ltd. Biotronics has been awarded a contract by the Veterinary Services...

Cyprus/Greece/MaltaCyprusGreeceMalta

12.08.2005

Athens - The Greek government announced in August a collaborative agreement between its contractor Antisel A. Selidis and US-based Genaissance Pharmaceuticals in the field of scrapie genotyping.Under the terms of the agreement,...

Cyprus/Greece/MaltaCyprusGreeceMalta

12.08.2005

La Valetta - After a broad discussion process Malta's Social Affairs Committee has presented a draft regulation on biotechnology and assisted reproduction to the parliament in July.According to the proposals the fertilised ovum...

Cyprus/Greece/MaltaCyprusGreeceMalta

10.07.2005

La Valletta - Synergene Biotechnology Group, a Malta-based biotech company, in line with its expansion programme has recently appointed several new members to the board of directors of Synergene Technologies Limited. The new...

Cyprus/Greece/MaltaCyprusGreeceMalta

10.07.2005

Valletta - In mid-June the Social Affairs Committee of the House of Representatives has ended its consultation process regarding the use of biotechnology in Malta. The Committee is currently discussing a report compiled by the...

Cyprus/Greece/MaltaCyprusGreeceMalta

10.05.2005

Athens - Greece supports the development of biotechnology but is wary of its side effects, Greek Development Minister Dimitris Sioufas said during the first national Greek biotechnology and food technology conference held on...

Cyprus/Greece/MaltaCyprusGreeceMalta

10.05.2005

Athens/Lugano - Helsinn Healthcare S.A., a Swiss pharmaceutical group, and Galenica, a Greek pharmaceutical company, announced recently the signing of an agreement granting Galenica the exclusive licence and distribution rights...

Cyprus/Greece/MaltaCyprusGreeceMalta

10.05.2005

Nicosia - Delivering the promise of nanotechnology to society for much-awaited products and jobs, hinges critically on transferring manufacturing technology to industrial production. For this purpose, the University of Cyprus...

Displaying results 21 to 30 out of 47

< Previous 21-30 Next >

© 2007-2014 BIOCOM

http://www.european-biotechnology-news.com/nc/news/messages-archive/archive-cyprus-greece-malta/browse/2/article/tumor-marker-studies-questioned.html

Events

All Events

Stock list

All quotes

TOP

  • 4SC1.17 EUR0.00%
  • ACTELION109.60 CHF0.00%
  • ADDEX3.10 CHF0.00%

FLOP

  • CYTOTOOLS31.45 EUR-0.47%
  • 4SC1.17 EUR0.00%
  • ACTELION109.60 CHF0.00%

TOP

  • CO.DON3.32 EUR32.8%
  • EPIGENOMICS3.83 EUR23.5%
  • PAION3.05 EUR23.0%

FLOP

  • ADDEX3.10 CHF-22.5%
  • EVOTEC3.08 EUR-16.1%
  • MEDIGENE3.93 EUR-15.5%

TOP

  • SANTHERA88.05 CHF2058.1%
  • CO.DON3.32 EUR286.0%
  • PAION3.05 EUR202.0%

FLOP

  • CYTOS0.24 CHF-94.0%
  • BIOFRONTERA2.20 EUR-39.7%
  • MERCK KGAA68.48 EUR-39.7%

No liability assumed, Date: 21.09.2014


Current issue

All issues

Product of the week

Products